Moderna's AI-Designed mRNA Cancer Therapy Succeeds in Phase 3 with Keytruda
timshi_ai · x · 2026-08-20
Moderna announced its individualized cancer therapy combined with Keytruda succeeded in a Phase 3 trial, showing mRNA's potential beyond vaccines.
VC firm KernaLabs says it bet three years ago, as LLMs rapidly progressed, that AI models could outperform human-led design to create better mRNAs — a direction now clinically validated. Musk previously commented that artificial RNA essentially makes curing diseases a software problem.
More from Research
- From Smallville Paper to $2B Simile AI Unicorn — TheTuringPost · 2026-08-20
- The Hundred-Page Language Models Book: Build LLMs with PyTorch — burkov · 2026-08-20
- Exploring AI Biological Reasoning: Can LLMs Predict Drug Perturbations Without External Models? — willccbb · 2026-08-20
- ROR: Dynamically switch optimizers during training — RichmanRonald · 2026-08-20
- FACET: Preserving Source Intent and Executable State in Terminal Task Synthesis — Kou Shi · 2026-08-20
- Fine-tuning Gemma 4 26B on 500k court decisions never beats the prompted base model — seruZ12 · 2026-08-20